The present disclosure provides a compound for inhibiting IDO, a manufacturing method and a use thereof. The compound is represented by the following general formula I,

##STR00001##

wherein a bond represented by a wavy line “” indicates the structure which represents independently a cis-isomer, a trans-isomer, or a mixture of cis- and trans-isomers; R.sub.1 and R.sub.2 are each independently selected from the group consisting of H, halogen, alkyl, alkoxyl, and haloalkyl; R.sub.3 is selected from the group consisting of cyclopentyl, cyclohexyl, piperazinyl, and piperidyl; and the substitution positions of are optionally substituted at 1,2 position, 1,3 position or 1,4 position; m and n are an integer number independently selected from 0 to 5. The compound of the present invention has a strong inhibiting effect on IDO and can be used to manufacture an IDO inhibitor for the prevention and/or treatment of an IDO-mediated disease with the pathologic features of the tryptophan metabolic pathway. The compound has very, good application potential.

The present invention provides a novel indoleamine 2,3-dioxygenase inhibitor, a preparation method thereof, and a pharmaceutical composition, in which the definitions of n, Y, Z, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as stated in the specification. Also provided is a use of the aforementioned compound and pharmaceutically acceptable salts and isomers thereof in the preparation of a drug for indoleamine 2,3-dioxygenase (IDO) related disease, specifically a use in the treatment of major diseases such as cancer, Alzheimer's, depression, cataract, etc. The compound of the invention has improved activity, potential medicinal value, and wide market prospects.

The present invention provides a novel indoleamine 2,3-dioxygenase inhibitor, a preparation method thereof, and a pharmaceutical composition, in which the definitions of n, Y, Z, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as stated in the specification. Also provided is a use of the aforementioned compound and pharmaceutically acceptable salts and isomers thereof in the preparation of a drug for indoleamine 2,3-dioxygenase (IDO) related disease, specifically a use in the treatment of major diseases such as cancer, Alzheimer's, depression, cataract, etc. The compound of the invention has improved activity, potential medicinal value, and wide market prospects.

A compound for inhibiting IDO represented by the following general formula I, ##STR00001## wherein a bond represented by a wavy line “” indicates the structure which represents independently a cis-isomer, a trans-isomer, or a mixture of cis- and trans-isomers; R.sub.1 and R.sub.2 are each independently selected from the group consisting of H, halogen, alkyl, alkoxyl, and haloalkyl; R.sub.3 is selected from the group consisting of cyclopentyl, cyclohexyl, piperazinyl, and piperidyl; and the substitution positions of R.sub.3 are optionally substituted at 1,2 position, 1,3 position or 1,4 position; m and n are an integer number independently selected from 0 to 5. The compound has a strong inhibiting effect on IDO and can be used to manufacture an IDO inhibitor for the prevention and/or treatment of an IDO-mediated disease with the pathologic features of the tryptophan metabolic pathway.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

A compound is represented by formula (I). A pharmaceutical composition contains the compound of formula (I). The compound is used in the preparation of an indoleamine-2,3-dioxygenase (IDO) inhibitor drug. The compound exhibits inhibition effect on IDO protease and metabolizes stably in the body. The compound or pharmaceutical composition thereof can be used for preparing an IDO inhibitor drug, and can also be used for preparing a drug for preventing and/or treating diseases having IDO-mediated tryptophan metabolic pathway pathological features.

##STR00001##

A compound is represented by formula (I). A pharmaceutical composition contains the compound of formula (I). The compound is used in the preparation of an indoleamine-2,3-dioxygenase (IDO) inhibitor drug. The compound exhibits inhibition effect on IDO protease and metabolizes stably in the body. The compound or pharmaceutical composition thereof can be used for preparing an IDO inhibitor drug, and can also be used for preparing a drug for preventing and/or treating diseases having IDO-mediated tryptophan metabolic pathway pathological features.

##STR00001##